Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool

January 28, 2020 By The ASCO Post

Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cancer treated with mFOLFOX6. The study showed that patients with an intermediate or high Immunoscore seemed to benefit from 6 months of mFOLFOX6 treatment compared with 3 months (Abstract 10).

Related Content